Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults

JAMA Netw Open. 2019 Oct 2;2(10):e1913612. doi: 10.1001/jamanetworkopen.2019.13612.

Authors

Abhishek Kumar¹, Vinit Nalawade¹, Paul Riviere¹, Reith R Sarkar¹, J Kellog Parsons², James D Murphy¹, Brent S Rose¹

Affiliations

¹ Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla.
² Department of Urology, University of California, San Diego, La Jolla.

Abstract

This cohort study examines the association between use of 5α-reductase inhibitors and prostate cancer mortality among US Medicare beneficiaries.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

5-alpha Reductase Inhibitors / therapeutic use*
Aged
Aged, 80 and over
Cohort Studies
Humans
Male
Medicare
Neoplasm Grading
Neoplasm Staging
Prostate-Specific Antigen / blood*
Prostatic Hyperplasia / drug therapy
Prostatic Neoplasms / blood
Prostatic Neoplasms / diagnosis
Prostatic Neoplasms / mortality*
Prostatic Neoplasms / pathology
SEER Program
United States / epidemiology

Substances

5-alpha Reductase Inhibitors
Prostate-Specific Antigen

Grants and funding

TL1 TR001443/TR/NCATS NIH HHS/United States